Related Experiment Video
Updated: May 17, 2025
Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Development and validation of an early diagnosis model for severe mycoplasma pneumonia in children based on
1Department of Laboratory Medicine, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430016, China.
Insights
This study developed a new model to predict severe Mycoplasma pneumoniae pneumonia (SMPP) in children. The SCRPT model uses five key indicators for early diagnosis, improving outcomes for pediatric pneumonia.
Area of Science:
- Pediatric Infectious Diseases
- Computational Biology
- Biomarker Discovery
Background:
- Pediatric pneumonia, particularly severe Mycoplasma pneumoniae pneumonia (SMPP), poses a significant health risk to children under five.
- Rising incidence of SMPP necessitates advanced early warning systems for improved patient prognosis.
Purpose of the Study:
- To develop and validate an accurate early warning model for predicting SMPP in pediatric patients.
- To identify key clinical and serological indicators for early SMPP detection.
- To create a simplified, clinically applicable diagnostic tool for SMPP.
Main Methods:
- Utilized Lasso regression and eight machine learning algorithms on data from 597 SMPP patients (1 month-18 years).
- Validated model performance using prospective cohort data and assessed clinical utility with DCA and CIC curves.
- Employed SHAP analysis to identify significant predictive variables for a simplified model.
Main Results:
- Eight machine learning models were built using age, sex, and 21 serum indicators; LightGBM achieved an AUC of 0.92.
- A simplified model (SCRPT) incorporating S100A8/A9, CT, RBP, P-LCR, and Treg cells showed strong diagnostic efficacy (AUC > 0.8).
- Serum S100A8/A9 demonstrated superior performance over standard markers in differentiating SMPP severity.
Conclusions:
- The SCRPT model, based on five key variables, offers a promising tool for the early diagnosis of SMPP in children.
- Serum S100A8/A9 serves as a valuable biomarker for assessing SMPP severity, especially in resource-limited settings.
Background:
Pneumonia is a major threat to the health of children, especially those under the age of five. Mycoplasma pneumoniae infection is a core cause of pediatric pneumonia, and the incidence of severe mycoplasma pneumoniae pneumonia (SMPP) has increased in recent years. Therefore, there is an urgent need to establish an early warning model for SMPP to improve the prognosis of pediatric pneumonia.
Methods:
The study comprised 597 SMPP patients aged between 1 month and 18 years. Clinical data were selected through Lasso regression analysis, followed by the application of eight machine learning algorithms to develop early warning model. The accuracy of the model was assessed using validation and prospective cohort. To facilitate clinical assessment, the study simplified the indicators and constructed visualized simplified model. The clinical applicability of the model was evaluated by DCA and CIC curve.
Results:
After variable selection, eight machine learning models were developed using age, sex and 21 serum indicators identified as predictive factors for SMPP. A Light Gradient Boosting Machine (LightGBM) model demonstrated strong performance, achieving AUC of 0.92 for prospective validation. The SHAP analysis was utilized to screen advantageous variables, which contains of serum S100A8/A9, tracheal computed tomography (CT), retinol-binding protein(RBP), platelet larger cell ratio(P-LCR) and CD4+CD25+Treg cell counts, for constructing a simplified model (SCRPT) to improve clinical applicability. The SCRPT diagnostic model exhibited favorable diagnostic efficacy (AUC > 0.8). Additionally, the study found that S100A8/A9 outperformed clinical inflammatory markers can also differentiate the severity of MPP.
Conclusions:
The SCRPT model consisting of five dominant variables (S100A8/A9, CT, RBP, PLCR and Treg cell) screened based on eight machine learning is expected to be a tool for early diagnosis of SMPP. S100A8/A9 can also be used as a biomarker for validity differentiation of SMPP when medical conditions are limited.
